Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease

Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease

Publication date: Oct 08, 2019

CAMBRIDGE, Mass. –(Business Wire)– Yumanity Therapeutics , a company focused on protecting the vitality of the mind by discovering and developing transformative brain-penetrating small molecule drugs to treat neurodegenerative diseases, today announced that the first subject cohort has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of YTX-7739 in healthy volunteers.

YTX-7739, the company’s lead investigational therapy, is designed to inhibit Stearoyl-CoA-Desaturase (SCD), a validated biologic target that has recently shown potential in neurodegenerative diseases by protecting cells from a-synuclein toxicity, a major driver of Parkinson’s disease.

-Developing effective therapies for patients with devastating neurodegenerative diseases has been challenging because too few hypotheses and novel targets have been explored,” said Kenneth Rhodes, Ph. D., chief scientific officer at Yumanity Therapeutics.

About YTX-7739 YTX-7739 is Yumanity Therapeutics’ proprietary lead investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target that plays an important and previously unrecognized role in the neurotoxicity caused by the a-synuclein protein, a major driver of Parkinson’s disease and related neurodegenerative disorders.

Formed in 2014 by renowned biotech industry leader, Tony Coles, M. D., and protein folding science pioneer, Susan Lindquist, Ph. D., the company is focused on discovering disease-modifying therapies for patients with Parkinson’s disease and related disorders, amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease.

Concepts Keywords
ALS Pharmacokinetics
Amyotrophic Lateral Sclerosis Parkinson’s disease
Biotech Senescence
Blood Brain Barrier Neuroscience
Blood Test Neurodegeneration
Bradykinesia Organ systems
Brain Branches of biology
Business Wire Investigational therapy
CAMBRIDGE Disturbances sensory dysfunction
Central Nervous System Potential neurodegenerative diseases
Chief Executive Officer Neurotoxicity subsequent disorders
Clinical Trial Slowness movement bradykinesia
CoA Related neurodegenerative diseases
Cognition Progressive neurological disorder
Cognitive Drug neurodegenerative diseases
Cohort Related disorders
Coles Extremities tremors
Crossover
Double Blind
Inhibitor
Misfolding
Neurodegeneration
Neurodegenerative Diseases
Neurodegenerative Disorders
Neurological Disorder
Neurotoxicity
Orally Active
Parkinson
Pathologies
Pharmacokinetics
Phenotypes
Placebo
Progressive
Protein
Rhodes
Richard Peters
Sleep Disturbances
Small Molecule
Stiffness
Tolerability
Toxicity

Semantics

Type Source Name
gene UNIPROT WIPF2
disease MESH neurodegenerative diseases
pathway BSID Neurodegenerative Diseases
drug DRUGBANK Nonoxynol-9
gene UNIPROT SCD
disease MESH development
disease DOID neurotoxicity
disease MESH neurological disorder
disease MESH disease progression
disease MESH bradykinesia
disease MESH tremors
disease MESH abnormalities
disease MESH diagnosis
pathway BSID Protein folding
disease MESH amyotrophic lateral sclerosis
disease DOID amyotrophic lateral sclerosis
gene UNIPROT IGFALS
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *